





PROTECTOR is supported by Barts and the London

Charity and The Rosetrees Trust

PROTECTOR Newsletter – October 2023

Welcome to the PROTECTOR newsletter!

We have now recruited over 1050 patients to the study and would like to thank all those involved to date. Total recruitment currently stands at **1058 patients.** PROTECTOR is now active at **42 sites**.

- PROTECTOR is registered with the **NIHR Associate PI Scheme.** Information about the scheme can be found in the attached presentation, please consider signing up!
- Thank you to the teams in **Edinburgh and Nottingham** who have performed very well recently! Thanks also goes to **Cambridge** for recruiting their first participants! Treats are on their way to all of you!
- You will have received a reminder email of outstanding data, including outstanding baseline questionnaires and surgery
 dates. We would appreciate if you can action these. The data from the baseline questionnaires is really important to us
 and we are aiming for a 100% response rate. We will be conducting another audit on this soon.
- Thank you to all sites and pathologist for your patience while the database was down. Apologies for the inconvenience caused, but we can now confirm all issues have now been resolved and data entry can resume as normal.

caused, but we can now commin an issues i	iave now bec
Site	Recruitment
Barts Health NHS Trust	113
Guy's and St Thomas' NHS Foundation Trust	84
St George's University Hospitals NHS Foundation Trust	69
Manchester University NHS Foundation Trust	67
Royal Surrey County Hospital NHS Foundation Trust	49
University College London Hospital Foundation Trust	44
Worcestershire Acute Hospital Trust	45
Nottingham University Hospitals NHS Trust	47
Brighton and Sussex University Hospitals NHS Trust	39
Belfast Health & Social Care Trust	43
University Hospitals Bristol NHS Foundation Trust	31
Cardiff and Vale NHS Trust	29
Liverpool Women's Hospital NHS Foundation Trust	35
Norfolk and Norwich University Hospitals	28
Portsmouth Hospitals NHS Trust	28
University Hospital Southampton NHS Foundation Trust	23
University Hospitals of Leicester NHS Trust	27
Ninewells Hospital, NHS Tayside	24
Royal Devon & Exeter NHS Foundation Trust	24
Royal Cornwall Hospitals NHS Trust	22
Northampton General Hospitals NHS Trust	19
Imperial College Healthcare NHS Trust	14
Aberdeen Royal Infirmary, NHS Grampian	15
Sandwell and West Birmingham Hospitals NHS Trust	18
East Lancashire Hospitals NHS Trust	15
North Tees and Hartlepool NHS Foundation Trust	11
County Durham and Darlington NHS Foundation Trust	10
Gateshead Health NHS Foundation Trust	13
Leeds Teaching Hospitals NHS Trust	19
East Kent Hospitals University NHS Foundation Trust	7
Ysbyty Gwynedd Hospital, Betsi Cadwaladr UHB	6
Maidstone and Tunbridge Wells NHS Trust	5
Newcastle upon Tyne Hospitals NHS Foundation Trust	5
NHS Greater Glasgow & Clyde	5
Royal Infirmary of Edinburgh, NHS Lothian	6
University Hospitals of Derby and Burton NHS Trust	3
Royal United Hospitals Bath NHS Foundation Trust	2
Northwick Park and St Mark's Hospitals	2
South Tyneside and Sunderland NHS Foundation Trust	1
South Tees Hospitals NHS Foundation Trust	2
Swansea Bay University Local Health Board	0
Cambridge University Hospitals NHS Trust	4



- The PROTECTOR study is open to BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, and PALB2 mutation carriers.
- Please notify us when a participant's surgery is scheduled or has happened.
- Per the new SOP, please post histopathology and cytology slides and blocks to the PROTECTOR team following local pathology review. Please notify us when slides are on the way and ensure slides are sent in a timely manner. Please also ensure slides/blocks are pseudo-anonymized prior to sending.
- You can contact the PROTECTOR team at <u>bci-protector@qmul.ac.uk</u>. Please do not send any patient identifiable information to this email. If you need to send us identifiable information, use our NHS email: protector.study@nhs.net.
- Please keep the study database up-to-date. Patient postal addresses on the Registration form should be current so questionnaires reach them. The baseline investigations and hormonal profile forms are important to determine eligibility.
- A reminder to <u>please complete baseline questionnaires in</u> <u>clinic</u> wherever possible and to contact patients whose <u>questionnaire is outstanding</u>.
- Completed Baseline questionnaires should be posted to the below address as soon as possible. Prepaid envelopes can be requested.

PROTECTOR Study Research Team Barts Cancer Institute, CECM Charterhouse Square London EC1M 6BQ

Study website: protector.org.uk
Twitter:@PROTECTOR QMUL

